Mutant p53 cooperates with ETS2 to promote etoposide resistance

Genes and Development

Volumn 26, Issue 8, 2012, Pages 830-845

  Do, Phi M ^a   Varanasi, Lakshman ^a   Fan, Songqing ^b   Li, Chunyang ^b   Kubacka, Iwona ^c   Newman, Virginia ^a   Chauhan, Krishna ^a   Daniels, Silvano Rakeem ^a   Boccetta, Maurizio ^d   Garrett, Michael R ^a   Li, Runzhao ^b   Martinez, Luis A ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Cancer; p53; TDP2

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; MUTANT PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR ETS 2;

APOPTOSIS; ARTICLE; BINDING SITE; CANCER RESISTANCE; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; DNA BINDING; DNA REPAIR; DRUG TARGETING; GAIN OF FUNCTION MUTATION; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG CANCER; OPEN READING FRAME; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; HUMANS; LUNG NEOPLASMS; MUTATION; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEIN C-ETS-2; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84859869155     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.181685.111     Document Type: Article

References (61)

1. Adhikari S, Karmahapatra SK, Elias H, Dhopeshwarkar P, Scott Williams R, Byers S, Uren A, Roy R. 2011. Development of a novel assay for human tyrosyl DNA phosphodiesterase 2. Anal Biochem 416: 112-116.
2. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, Solari A, Bobisse S, Rondina MB, Guzzardo V, et al. 2009. A Mutant-p53/Smad complex opposes p63 to empower TGFb-induced metastasis. Cell 137: 87-98.
3. Babayeva ND, Wilder PJ, Shiina M, Mino K, Desler M, Ogata K, Rizzino A, Tahirov TH. 2010. Structural basis of Ets1 cooperative binding to palindromic sequences on stromelysin-1 promoter DNA. Cell Cycle 9: 3054-3062.
4. Bailey TL, Elkan C. 1994. Fitting a mixture model by expectation maximization to discover motifs in biopolymers. Proc Int Conf Intell Syst Mol Biol 2: 28-36.
5. Basuyaux JP, Ferreira E, Stehelin D, Buttice G. 1997. The Ets transcription factors interact with each other and with the c-Fos/c-Jun complex via distinct protein domains in a DNA-dependent and -independent manner. J Biol Chem 272: 26188-26195.
6. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, et al. 2003. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3: 387-402.
7. Bischoff FZ, Yim SO, Pathak S, Grant G, Siciliano MJ, Giovanella BC, Strong LC, Tainsky MA. 1990. Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: Aneuploidy and immortalization. Cancer Res 50: 7979-7984.
8. Blandino G, Levine AJ, Oren M. 1999. Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18: 477-485.
9. Botcheva K, McCorkle SR, McCombie WR, Dunn JJ, Anderson CW. 2011. Distinct p53 genomic binding patterns in normal and cancer-derived human cells. Cell Cycle 10: 4237-4249.
10. Brosh R, Rotter V. 2009. When mutants gain new powers: News from the mutant p53 field. Nat Rev Cancer 9: 701-713.
11. Charlot C, Dubois-Pot H, Serchov T, Tourrette Y, Wasylyk B. 2010.A review of post-translational modifications and sub- cellular localization of Ets transcription factors: Possible connection with cancer and involvement in the hypoxic response. Methods Mol Biol 647: 3-30.
12. Cortes Ledesma F, El Khamisy SF, Zuma MC, Osborn K, Caldecott KW. 2009. A human 59-tyrosyl DNA phospho-diesterase that repairs topoisomerase-mediated DNA damage. Nature 461: 674-678.
13. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A, Blandino G, Piaggio G. 2006. Gain of function of mutant p53: The mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10: 191-202.
14. Di Como CJ, Gaiddon C, Prives C. 1999. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 19: 1438-1449.
15. Esguerra CV, Nelles L, Vermeire L, Ibrahimi A, Crawford AD, Derua R, Janssens E, Waelkens E, Carmeliet P, Collen D, et al. 2007. Ttrap is an essential modulator of Smad3-dependent Nodal signaling during zebrafish gastrulation and left-right axis determination. Development 134: 4381-4393.
16. Fontemaggi G, Dell'Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, Terrenato I, Mottolese M, Muti P, Domany E, et al. 2009. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol 16: 1086-1093.
17. Fujiwara S, Fisher RJ, Bhat NK, Diaz de la Espina SM, Papas TS. 1988. A short-lived nuclear phosphoprotein encoded by the human ets-2 proto-oncogene is stabilized by activation of protein kinase C. Mol Cell Biol 8: 4700-4706.
18. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C. 2001. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 21: 1874-1887.
19. Gu L, Zhu N, Findley HW, Woods WG, Zhou M. 2004. Identification and characterization of the IKKa promoter: Positive and negative regulation by ETS-1 and p53, respectively. J Biol Chem 279: 52141-52149.
20. Gupta S, Stamatoyannopoulos JA, Bailey TL, Noble WS. 2007. Quantifying similarity between motifs. Genome Biol 8: R24. doi: 10.1186/gb-2007-8-2-r24.
21. Hoh J, Jin S, Parrado T, Edington J, Levine AJ, Ott J. 2002. The p53MH algorithm and its application in detecting p53-re-sponsive genes. Proc Natl Acad Sci 99: 8467-8472.
22. Hollenhorst PC, Chandler KJ, Poulsen RL, Johnson WE, Speck NA, Graves BJ. 2009. DNA specificity determinants associate with distinct transcription factor functions. PLoS Genet 5: e1000778. doi: 10.1371/journal.pgen.1000778.
23. Hollenhorst PC, McIntosh LP, Graves BJ. 2011. Genomic and biochemical insights into the specificity of ETS transcription factors. Annu Rev Biochem 80: 437-471.
24. Huang da W, Sherman BT, Lempicki RA. 2009. Systematic and integrative analysis of large gene lists using DAVID bioin-formatics resources. Nat Protoc 4: 44-57.
25. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG Jr. 2003. Chemosensitivity linked to p73 function. Cancer Cell 3: 403-410.
26. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B. 1991. Identification of p53 as a sequence-specific DNA-binding protein. Science 252: 1708-1711.
27. Kim E, Gunther W, Yoshizato K, Meissner H, Zapf S, Nusing RM, Yamamoto H, Van Meir EG, Deppert W, Giese A. 2003. Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1. Oncogene 22: 7716-7727.
28. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, et al. 2004. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861-872.
29. Li Y, Prives C. 2007. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 26: 2220-2225.
30. Li C, Fan S, Owonikoko TK, Khuri FR, Sun SY, Li R. 2011a. Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway. Oncogene 30: 3802-3812.
31. Li C, Sun SY, Khuri FR, Li R. 2011b. Pleiotropic functions of EAPII/TTRAP/TDP2: Cancer development, chemoresis-tance and beyond. Cell Cycle 10: 3274-3283.
32. Liu Y, Asch H, Kulesz-Martin MF. 2001. Functional quantification of DNA-binding proteins p53 and estrogen receptor in cells and tumor tissues by DNA affinity immunoblotting. Cancer Res 61: 5402-5406.
33. Lozano G, Zambetti GP. 2005. What have animal models taught us about the p53 pathway? J Pathol 205: 206-220.
34. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, et al. 2000. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25: 47-54.
35. Mavrothalassitis G, Ghysdael J. 2000. Proteins of the ETS family with transcriptional repressor activity. Oncogene 19: 6524-6532.
36. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, Lukashchuk N, Gillespie DA, Ludwig RL, Gosselin P, et al. 2009. Mutant p53 drives invasion by promoting integrin recycling. Cell 139: 1327-1341.
37. Muller PA, Vousden KH, Norman JC. 2011. p53 and its mutants in tumor cell migration and invasion. J Cell Biol 192: 209-218.
38. Pastorcic M, Das HK. 2000. Regulation of transcription of the human presenilin-1 gene by ets transcription factors and the p53 protooncogene. J Biol Chem 275: 34938-34945.
39. Pei H, Yordy JS, Leng Q, Zhao Q, Watson DK, Li R. 2003. EAPII interacts with ETS1 and modulates its transcriptional function. Oncogene 22: 2699-2709.
40. Pype S, Declercq W, Ibrahimi A, Michiels C, Van Rietschoten JG, Dewulf N, de Boer M, Vandenabeele P, Huylebroeck D, Remacle JE. 2000. TTRAP, a novel protein that associates with CD40, tumor necrosis factor (TNF) receptor-75 and TNF receptor-associated factors (TRAFs), and that inhibits nuclear factor-kB activation. J Biol Chem 275: 18586-18593.
41. Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, Wang Q, Zambetti GP, Schuetz JD. 2001. Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 276: 39359-39367.
42. Sankala H, Vaughan C, Wang J, Deb S, Graves PR. 2011. Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresist-ance. Arch Biochem Biophys 512: 52-60.
43. Smeenk L, van Heeringen SJ, Koeppel M, van Driel MA, Bartels SJ, Akkers RC, Denissov S, Stunnenberg HG, Lohrum M. 2008. Characterization of genome-wide p53-binding sites upon stress response. Nucleic Acids Res 36: 3639-3654.
44. Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, Shiff I, Kogan I, Shay M, Kalo E, et al. 2010. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 17: 273-285.
45. Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L, Levine AJ, Sacchi A, Cesareni G, Oren M, et al. 2000. Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem 275: 29503-29512.
46. Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A, Del Sal G, Levrero M, Sacchi A, Oren M, et al. 2002. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 277: 18817-18826.
47. Sun H, Yuan Y, Wu Y, Liu H, Liu JS, Xie H. 2010. Tmod: Toolbox of motif discovery. Bioinformatics 26: 405-407.
48. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD. 1989. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494.
49. Tseng JE, Rodriguez M, Ro J, Liu D, Hong WK, Mao L. 1999. Gender differences in p53 mutational status in small cell lung cancer. Cancer Res 59: 5666-5670.
50. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, et al. 2006. A global map of p53 transcription-factor binding sites in the human genome. Cell 124: 207-219.
51. Weinmann AS, Yan PS, Oberley MJ, Huang TH, Farnham PJ. 2002. Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microarray analysis. Genes Dev 16: 235-244.
52. Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, Rotter V. 2004. Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res 64: 8318-8327.
53. Weisz L, Oren M, Rotter V. 2007. Transcription regulation by mutant p53. Oncogene 26: 2202-2211.
54. Wistuba II, Gazdar AF, Minna JD. 2001. Molecular genetics of small cell lung carcinoma. Semin Oncol 28: 3-13.
55. Xu D, Wilson TJ, Chan D, De Luca E, Zhou J, Hertzog PJ, Kola I. 2002. Ets1 is required for p53 transcriptional activity in UV-induced apoptosis in embryonic stem cells. EMBO J 21: 4081-4093.
56. Yan W, Chen X. 2009. Identification of GRO1 as a critical determinant for mutant p53 gain of function. J Biol Chem 284: 12178-12187.
57. Yan W, Liu G, Scoumanne A, Chen X. 2008. Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations. Cancer Res 68: 6789-6796.
58. Yan L, Zhang D, Chen C, Mao Y, Xie Y, Li Y, Huang Y, Han B. 2009. TP53 Arg72Pro polymorphism and lung cancer risk: A meta-analysis. Int J Cancer 125: 2903-2911.
59. Zalcenstein A, Weisz L, Stambolsky P, Bar J, Rotter V, Oren M. 2006. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. Oncogene 25: 359-369.
60. Zeng Z, Cortes-Ledesma F, El Khamisy SF, Caldecott KW. 2011. TDP2/TTRAP is the major 59-tyrosyl DNA phosphodiester-ase activity in vertebrate cells and is critical for cellular resistance to topoisomerase II-induced DNA damage. J Biol Chem 286: 403-409.
61. Zucchelli S, Vilotti S, Calligaris R, Lavina ZS, Biagioli M, Foti R, De Maso L, Pinto M, Gorza M, Speretta E, et al. 2009. Aggresome-forming TTRAP mediates pro-apoptotic properties of Parkinson's disease-associated DJ-1 missense mutations. Cell Death Differ 16: 428-438.